No one can give you a firm date for when aging will be fully reversible, but the science is closer than most people realize. Several approaches to slowing or partially reversing biological aging are already in human trials, and the most optimistic predictions place meaningful breakthroughs within the next decade. The honest answer is that pieces of age reversal are happening now in labs and small clinical studies, while a comprehensive, accessible treatment for the general public is likely still 15 to 30 years away, depending on which expert you ask and how you define “reverse aging.”
What “Reversing Aging” Actually Means
Before any timeline makes sense, it helps to understand what scientists are actually trying to reverse. Aging isn’t one thing. It’s a collection of processes: cells stop dividing and become “senescent,” DNA accumulates damage, the protective caps on your chromosomes (telomeres) shorten, inflammation rises, and the chemical tags on your DNA that control gene activity drift out of their youthful patterns. Reversing aging means pushing back on some or all of these processes so that your body functions like a younger version of itself.
Scientists now measure biological age using epigenetic clocks, which read chemical markers on your DNA and estimate how old your body really is compared to your calendar age. The most widely used clock, developed by Steve Horvath, has an average error of about 3.6 years. Newer versions like GrimAge do a better job predicting physical decline, tracking things like walking speed, grip strength, and cognitive function. These clocks give researchers a concrete way to test whether an intervention actually makes someone biologically younger, not just healthier. When you see headlines about someone “reversing their age by five years,” this is the yardstick being used.
Clearing Out Old Cells With Senolytics
One of the most advanced approaches targets senescent cells, sometimes called “zombie cells.” These are cells that have stopped dividing but refuse to die. They pile up with age, leak inflammatory signals, and damage surrounding tissue. Drugs called senolytics are designed to selectively kill these cells.
The first human trial of a senolytic combination (dasatinib plus quercetin) tested nine people with diabetic kidney disease, averaging about 69 years old. After just three days of treatment, fat tissue biopsies taken 11 days later showed a 35% reduction in one key marker of senescent cells and a 62% drop in another. Immune cells called macrophages, which cluster around damaged tissue, dropped 28%. Clusters of inflammatory cells fell by 86%. Skin biopsies showed similar improvements, with senescent cell markers declining 20 to 31%. Blood levels of several inflammatory proteins also dropped significantly.
A separate trial showed that senolytics improved physical function in patients with idiopathic pulmonary fibrosis, a fatal lung disease driven by cell senescence. These are small, early studies, but the signal is strong: clearing senescent cells produces measurable rejuvenation in human tissue within days.
Reprogramming Cells to a Younger State
The most ambitious approach to age reversal is called partial cellular reprogramming. The basic idea is to take an old cell and rewind its identity partway back toward a stem-cell-like state, restoring youthful gene activity without erasing the cell’s specialized function. This uses a set of proteins called Yamanaka factors, which won a Nobel Prize in 2012 for their ability to turn adult cells back into stem cells.
The challenge is control. Push reprogramming too far and cells lose their identity entirely, which in animal experiments has led to tumor formation (teratomas) across multiple organs. The Yamanaka factors are also inherently cancer-promoting, which limits their therapeutic use right now. Researchers are working on ways to deliver these factors in precise, short pulses to get the rejuvenation benefits without the cancer risk. Animal studies have shown promising results, restoring youthful function in aged mice, but the gap between “works in mice” and “safe in humans” remains significant. No human trials of in vivo reprogramming for aging have been completed.
Gene Therapy for Telomeres
Telomeres, the protective caps on the ends of your chromosomes, shorten every time a cell divides. When they get too short, cells malfunction or die. One gene therapy approach uses a gene called ZSCAN4 to extend telomeres in blood-forming stem cells. In two patients with telomere biology disorders (genetic conditions that cause premature aging of the bone marrow), the therapy successfully lengthened telomeres and improved immune cell counts without major side effects. In one patient, telomere length also increased in immune cells circulating in the blood.
This therapy was designed for a rare disease, not general aging. But it demonstrates that telomere extension is achievable in humans and that the safety concerns, particularly cancer from unchecked cell growth, can be managed, at least in the short term.
Drugs That May Slow the Clock
Two existing drugs get the most attention in longevity circles. Rapamycin, an immune-suppressing drug used in organ transplants, has extended lifespan in nearly every organism it’s been tested on. In humans, low doses of rapamycin derivatives have been shown to boost immune response in older adults, essentially reversing age-related immune decline. A trial of 1 mg daily for eight weeks in healthy people showed no effect on cognitive function, which is reassuring from a safety standpoint but also means cognitive benefits haven’t been demonstrated yet.
Metformin, a cheap diabetes drug taken by millions of people, has shown associations with longer lifespan in diabetic patients compared to non-diabetic controls, which is unusual since diabetes typically shortens life. The landmark TAME (Targeting Aging with Metformin) trial was designed to recruit people aged 65 to 80 and follow them for six years to test whether metformin slows aging in non-diabetic adults. As of 2025, the trial has not launched due to funding shortfalls. This delay illustrates a broader problem: aging research struggles to attract the same investment as single-disease research because the regulatory framework doesn’t support it.
The Regulatory Bottleneck
The U.S. Food and Drug Administration does not classify aging as a disease. No drug has ever been approved to treat human aging itself, only age-related conditions like Alzheimer’s or osteoporosis. This distinction matters enormously. Drug companies can’t run a clinical trial with “aging” as the condition they’re treating, which means every potential anti-aging therapy has to be tested against a specific disease first. Two citizen petitions were submitted to the FDA asking for aging to be reclassified as a treatable condition. The agency declined to comment on the petitions, with a spokesperson referring to aging as a “natural process.”
If aging were recognized as a medical condition, it would open the door for drugs to be approved specifically for slowing or reversing it. Without that classification, each therapy has to take a longer, more expensive path through trials for individual diseases, then be used off-label by longevity-minded physicians. This regulatory stance could delay widespread access to anti-aging treatments by a decade or more, even after the science is ready.
The Predictions
Ray Kurzweil, the computer scientist and futurist who spent years as a Google engineer, predicted in March 2024 that humanity will reach “longevity escape velocity” by 2029. That’s the theoretical point where medical advances extend your remaining lifespan by more than one year for every year that passes. “Past 2029, you’ll get back more than a year. Go backwards in time,” Kurzweil said. He has a mixed track record on predictions, having correctly anticipated the rise of the internet and smartphones while being overly optimistic about other timelines.
Most biogerontologists are more conservative. The general consensus among researchers is that therapies capable of meaningfully slowing aging in healthy humans could reach clinical use in the 2030s, particularly senolytics and reprogramming-based approaches. Full reversal, where a 70-year-old could be restored to the biology of a 40-year-old, remains a much longer-term goal with no credible timeline.
Lifestyle interventions can already shift your epigenetic age. Exercise, stress reduction, and dietary changes have been shown to “rewind” epigenetic clocks, pushing DNA methylation patterns toward a more youthful state. These aren’t dramatic reversals, but they’re real, measurable, and available now. For most people searching this question, the practical answer is a split one: partial age reversal through lifestyle and early therapeutics is beginning now, while the transformative breakthroughs that would make aging truly optional are still working their way through labs, trials, and regulatory hurdles that could take another one to three decades to clear.